1. Home
  2. HQH vs MNKD Comparison

HQH vs MNKD Comparison

Compare HQH & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Healthcare Investors Shares of Beneficial Interest

HQH

abrdn Healthcare Investors Shares of Beneficial Interest

HOLD

Current Price

$24.26

Market Cap

1.3B

Sector

Finance

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$4.17

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HQH
MNKD
Founded
1986
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
HQH
MNKD
Price
$24.26
$4.17
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$8.69
AVG Volume (30 Days)
241.5K
4.8M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
11.56%
N/A
EPS Growth
N/A
N/A
EPS
1.09
N/A
Revenue
N/A
$348,966,000.00
Revenue This Year
N/A
$35.81
Revenue Next Year
N/A
$11.89
P/E Ratio
$21.87
N/A
Revenue Growth
N/A
22.23
52 Week Low
$16.10
$2.23
52 Week High
$24.85
$6.51

Technical Indicators

Market Signals
Indicator
HQH
MNKD
Relative Strength Index (RSI) 69.16 56.27
Support Level $18.50 $3.74
Resistance Level N/A $4.55
Average True Range (ATR) 0.45 0.21
MACD 0.08 0.04
Stochastic Oscillator 79.18 77.92

Price Performance

Historical Comparison
HQH
MNKD

About HQH abrdn Healthcare Investors Shares of Beneficial Interest

abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: